{"name":"Karo Bio AB","slug":"karo-bio-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Eprotirome and ezetimibe","genericName":"Eprotirome and ezetimibe","slug":"eprotirome-and-ezetimibe","indication":"Hypercholesterolemia","status":"phase_2"}]}],"pipeline":[{"name":"Eprotirome and ezetimibe","genericName":"Eprotirome and ezetimibe","slug":"eprotirome-and-ezetimibe","phase":"phase_2","mechanism":"Eprotirome is a thyroid hormone receptor antagonist, and ezetimibe is a cholesterol absorption inhibitor.","indications":["Hypercholesterolemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMEdVMWxGejJRMGZIVjRVZ3dTRUdSQVUtV05ranFHSHdkQXhtR2p5OVFGR2NxNU1XUG90ei01VTRzOEhQX2tkUnBrQno3LXRzZ2tZNk5sUHJlZllmNFdkR2tWMzVqampPUnFlSkNvLWdNTm1ORGhfdXlRMlhRM1pta3NacEFveTRINWpfQXpYZUZBYVliZTA5NWd5RFkyMzJXNkRjeHB3blgtdw?oc=5","date":"2022-04-20","type":"pipeline","source":"White & Case LLP","summary":"White & Case advises Karo Pharma AB on SEK 2.5 billion rights issue - White & Case LLP","headline":"White & Case advises Karo Pharma AB on SEK 2.5 billion rights issue - White & Case LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPdi0tMXRDMU5wa2ZVTDFibUd0RndwT1BUZWZRdWNpbXZ1VThhek9hYnhNby1GTnFwYWFGNlY1dzBxMjBNb1psNTA2ajhmWXJHMXVwUy1JdXR6S0h6S21HZHliNzVFbUJnWUpVS0JVakNuS1pRcUdwY3kxSVQ2WjRTMms1SVgzRlpBYzJNdlN0RzFXajdYMThRUm9RVjVsd09VbXFwNE9PME9MMExmME4w?oc=5","date":"2022-04-19","type":"pipeline","source":"Osborne Clarke","summary":"Osborne Clarke advises Sylphar NV and Karo Pharma AB on purchase of Satin Naturel - Osborne Clarke","headline":"Osborne Clarke advises Sylphar NV and Karo Pharma AB on purchase of Satin Naturel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxOaHF1OUI2UkNlVTNVWExGaURQcGg1VHVnMUdxTlkxMW9RTnNuM2VfR0dUcnJ2aDR5WE5aQlZkVjRnUDhab1NsRE5SNWJRWHpmSDVidU5wSEhEMk5SRnlkeU5GODl2NEtRUE1xOEJfM2s1dUZmVWdDNC1WS1A5VWR3dkh6SlZxbmZ3SS1nZ0tDUkQweXNfYTJiczhFejZPOXR6c3dBRkNnMzAzZzd0RWVPRHBCa3dzMUg4MXpIMnFsamU4T0VUMU9URVprd3BXejZ5cEZqblVoa1VWZ0NkYjY2REdPeWlFWUNQeFlwVU5YVGQyRjhZMk50bktWUDhLYm9WNjI0?oc=5","date":"2021-02-24","type":"pipeline","source":"Business Wire","summary":"EpiEndo Pharmaceuticals Appoints Maria Bech as New Chief Executive Officer to Support Move into Clinical Development - Business Wire","headline":"EpiEndo Pharmaceuticals Appoints Maria Bech as New Chief Executive Officer to Support Move into Clinical Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOa0VzLTBTYjFGMUg2VWZsbm1YLWFaNUtUbWowQVpyMHoxLXI2Q0dFWmh1eGNzZWhmc1JtcWphWjVrVHFvQVJlVko4TF9faE84UklzdXFPN0VRZXVmbzlSTFBIXzZrcmF1YWNDc3VkM3R0VnRzZHpuQzUyRkFRMGxhYndJSQ?oc=5","date":"2019-06-21","type":"deal","source":"European Biotechnology Magazine","summary":"Karo Pharma acquires Trimb AB - European Biotechnology Magazine","headline":"Karo Pharma acquires Trimb AB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE05WUh0WWNybUpKQkh5Rk1XU2JvRGRIQ2xrTzBUMmJnUEhLZTFmaWlfUDlOd0w0NWRub0pVN3JfN3g4V0dmUG5LaGdQSkE1akVOUEFZb2plNGs0UkNkdmc?oc=5","date":"2018-02-09","type":"pipeline","source":"Nature","summary":"Targeting estrogen receptor beta (ERβ) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ERβ expression and functionality | Oncogenesis - Nature","headline":"Targeting estrogen receptor beta (ERβ) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ERβ expression","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}